We are live on ! Find out more
ABUS icon

Arbutus Biopharma
ABUS

99 hedge funds and large institutions have $149M invested in Arbutus Biopharma in 2021 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 31 increasing their positions, 23 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more call options, than puts

Call options by funds: $13.5M | Put options by funds: $7.71M

70% more capital invested

Capital invested by funds: $87.5M → $149M (+$61.2M)

64% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 14

35% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 23

9% more funds holding

Funds holding: 91 → 99 (+8)

5.19% more ownership

Funds ownership: 29.99% → 35.18% (+5.2%)

Holders
99
Holders Change
+8
Holders Change %
+8.79%
% of All Funds
1.73%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
23
Increased
31
Reduced
23
Closed
14
Calls
$13.5M
Puts
$7.71M
Net Calls
+$5.81M
Net Calls Change
+$8M

Top Buyers

1
Millennium Management
Millennium Management
New York
+$3.4M
2
N
Nuveen
North Carolina
+$2.98M
3
Barclays
Barclays
United Kingdom
+$2.08M
4
SG Americas Securities
SG Americas Securities
New York
+$2M
5
State Street
State Street
Massachusetts
+$1.67M

Top Sellers

1
RI
RTW Investments
New York
-$4.15M
2
Deutsche Bank
Deutsche Bank
Germany
-$1.1M
3
CAC
Cowen and Company
New York
-$720K
4
Two Sigma Advisers
Two Sigma Advisers
New York
-$363K
5
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$361K
Name Holding Trade Value Shares
Change 		Change in
Stake
EMG
51
ETF Managers Group
New Jersey
$155K +$25.8K +7,756 +27%
New York State Common Retirement Fund
52
New York State Common Retirement Fund
New York
$143K -$112K -33,578 -50%
Belvedere Trading
53
Belvedere Trading
Illinois
$140K +$112K +33,705 New
VOYA Investment Management
54
VOYA Investment Management
Georgia
$137K – – –
ProShare Advisors
55
ProShare Advisors
Maryland
$135K -$20.3K -6,103 -16%
MIM
56
MetLife Investment Management
New Jersey
$129K +$100K +30,042 New
Invesco
57
Invesco
Georgia
$126K +$13.3K +3,994 +16%
MLICM
58
Metropolitan Life Insurance Company (MetLife)
New York
$97.5K +$75.7K +22,728 New
ECM
59
ExodusPoint Capital Management
New York
$95K +$73.9K +22,184 New
Simplex Trading
60
Simplex Trading
Illinois
$94K +$830 +249 +0.8%
HighTower Advisors
61
HighTower Advisors
Illinois
$82K +$63.5K +19,065 New
HF
62
HRT Financial
New York
$80K +$62.4K +18,724 New
WMA
63
Wealth Management Associates
New Jersey
$71.9K -$2.33K -700 -4%
MAM
64
Meeder Asset Management
Ohio
$70K -$23.9K -7,168 -30%
BNP Paribas Financial Markets
65
BNP Paribas Financial Markets
France
$67.6K +$31.1K +9,318 +145%
Citigroup
66
Citigroup
New York
$63K +$17.1K +5,117 +54%
AllianceBernstein
67
AllianceBernstein
Tennessee
$60K – – –
CSS
68
Cubist Systematic Strategies
Connecticut
$58K -$167K -50,100 -79%
BSW
69
Buckingham Strategic Wealth
Missouri
$55K +$3.33K +1,000 +9%
XT
70
XTX Topco
Cayman Islands
$50K +$38.7K +11,604 New
SPC
71
Sigma Planning Corp
Michigan
$47K -$50K -15,000 -58%
LPL Financial
72
LPL Financial
California
$45K – – –
SAM
73
Secure Asset Management
Michigan
$43K – – –
Russell Investments Group
74
Russell Investments Group
United Kingdom
$36K -$15.4K -4,614 -35%
CM
75
Caption Management
Oklahoma
$30K -$106K -31,802 -82%
1 2
3
4 5

ABUS Hedge Fund Activity: Q3 2021 in Review

99 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q3 2021, worth a combined $149M — up 70% from $87.5M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new ABUS positions and 14 closed out — a net gain of 9 holders — while 31 added to existing stakes and 23 trimmed.

The largest buyer was Millennium Management, opening a new position worth an estimated $3.4M. The largest seller was RTW Investments, cutting an estimated $4.15M.

  • 99 institutional investors held Arbutus Biopharma (ABUS) as of Q3 2021, up from 91 in Q2 2021.
  • Funds reported $149M of Arbutus Biopharma stock for Q3 2021, up 70% quarter-over-quarter.
  • 23 funds opened new Arbutus Biopharma positions in Q3 2021 and 14 closed out, a net change of +9 holders.
  • The largest Arbutus Biopharma buyer in Q3 2021 was Millennium Management, an estimated $3.4M added.
  • The largest Arbutus Biopharma seller in Q3 2021 was RTW Investments, an estimated $4.15M sold.

Based on aggregated 13F filings for Q3 2021.